<DOC>
	<DOCNO>NCT02709876</DOCNO>
	<brief_summary>A single arm , single center trial evaluate safety efficacy autologous purified population bone-marrow derived stem cell patient Retinitis Pigmentosa ( BM-SCs ) 48 month follow period .</brief_summary>
	<brief_title>Autologous Bone Marrow-Derived CD34+ , CD133+ , CD271+ Stem Cell Transplantation Retinitis Pigmentosa</brief_title>
	<detailed_description>Retinitis pigmentosa ( RP ) inherit disorder photoreceptor cell retina . Patients may lose vision since young later life . Currently , 60 gene identify cause condition , one , RPE65 , study several gene therapy trial Leber congenital amaurosis promising result . Another treatment approach RP stem cell therapy . Studies animal model RP show subretinal injection bone marrow-derived mesenchymal stem cell may delay degenerative change photoreceptor cell . This single arm , single center trial ass safety efficacy purify adult autologous bone marrow derive CD34+ , CD133+ , CD271+ stem cell 48 month follow-up period . The combination three cell type base diverse potentiality differentiate specific functional cell type regenerate damage retinal tissue , availability clinical-grade purification system ( CliniMACS ) microbeads purify target cell population clinically-approved method .</detailed_description>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Retinitis Pigmentosa</mesh_term>
	<criteria>Retinitis pigmentosa patient diagnosed ophthalmologist Visual acuity ( measure ETDRS ) less equal 20/70 visual field 30Â° central eye . Best correct visual acuity le 6/120 Snellen visual acuity chart Other eye condition could mask interpretation result Unable return follow Underlying disease include asthma , heart failure , myocardial infarction , liver failure , renal failure Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>